Valo and Charles River's Logica platform identified an advanceable candidate for lupus and autoimmune disease.

Logica joins Valo's Opal platform and DNA-encoded libraries with Charles River's screening and discovery expertise as a target-to-candidate offering. The release reports the first Logica-identified advanceable candidate for lupus and other autoimmune conditions, with no timelines or efficacy data.

Valo Health is an AI drug discovery company whose Opal platform combines real-world patient data and computation to find targets and small molecules for partners.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.